Preparation and use of aryl alkyl acid derivatives for the treatment of obesity

A compound of Formula (I)

• wherein
• Q is O or S;
• A is a linker selected from
• wherein p is 1 or 2
• and
• wherein m is 0 and n is 1, 2, 3, or 4,
• or
• m is 1 and n is 1, 2, or 3,
• and
• wherein said linker is optionally substituted by one or two R8 groups;
• R1 and R2 are independently selected from hydrogen, halo, (C1-C6)alkyl, and (C1-C6)alkoxy;
• R3 is selected from
• hydrogen,
• (C1-C6)alkyl optionally substituted by hydroxy,
• and
• phenyl optionally substituted with (C1-C6)alkyl, (C1-C6)alkoxy, or halo;
• R4 is selected from hydrogen, nitro, and (C1-C6)alkyl;
• or
• R3 and R4 may, when taken together with the carbon atoms to which they are attached, form a benzene ring optionally substituted with up to two substituents selected from
• halo, (C1-C6)alkyl, (C1-C6)alkoxy, nitro, cyano, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, aminocarbonyl, (C1-C6)alkylaminocarbonyl, bis[(C1-C6)alkyl]aminocarbonyl, aminosulfonyl, (C1-C6)alkylaminosulfonyl, bis[(C1-C6)alkyl]aminosulfonyl, (C1-C6)alkylcarbonylamino, (C1-C6)alkylsulfonylamino, hydroxy-(C2-C6)alkylaminocarbonyl, 1-morpholinylcarbonyl, and 1-piperidinylcarbonyl,
• and
• when two of said benzene ring substituents are (C1-C6)alkyl and are attached to adjacent carbon atoms of the benzene ring, they may be joined together to form a 5-7-membered carbocyclic ring;
• R5 is hydrogen or (C1-C6)alkyl;
• R6 is hydrogen;
• R7 is hydrogen
• or
• (C1-C6)alkyl optionally substituted with
• (C1-C6)alkoxy,
• bis[(C1-C3)alkyl]amino
• or
• phenyl optionally substituted with halo, (C1-C6)alkyl, (C1-C6)alkoxy, or cyano;
• or
• R6 and R7 are both (C1-C6)alkyl;
• or
• R6 and R7 may form, together with the carbon atom to which they are attached,
• a 3- to 5-membered carbocyclic ring,
• or
• a 6-membered ring represented by
• wherein W is CH2, C(CH3)2, O, NR9, S, or SO2;
• R8 is (C1-C6)alkyl;
• and
• R9 is hydrogen or (C1-C6)alkyl;
• or the pharmaceutically acceptable salts and esters thereof.